Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Poxel S.A. (7PO.F)

Compare
0.4510
-0.0580
(-11.39%)
At close: April 15 at 8:07:56 AM GMT+2
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
2,188
1,981
674
13,397
6,806
Cost of Revenue
2,171
1,980
672
59
--
Gross Profit
17
1
2
13,339
6,806
Operating Expense
9,214
28,764
21,892
35,801
36,625
Operating Income
-9,197
-28,763
-21,890
-22,462
-29,819
Net Non Operating Interest Income Expense
-6,577
-6,148
-4,309
-2,950
-1,665
Pretax Income
-16,103
-35,088
-31,396
-23,760
-31,794
Tax Provision
2
2
2
2
36
Net Income Common Stockholders
-16,105
-35,090
-31,398
-23,763
-31,831
Diluted NI Available to Com Stockholders
-16,105
-35,090
-31,398
-23,763
-31,831
Basic EPS
-0.40
-0.91
-1.08
-0.83
-1.16
Diluted EPS
-0.40
-0.91
-1.08
-0.83
-1.16
Basic Average Shares
39,169.1040
38,602.6110
29,076.7160
28,642.3340
27,528.7830
Diluted Average Shares
39,169.1040
38,602.6110
29,076.7160
28,642.3340
27,528.7830
Total Operating Income as Reported
-9,200
-28,764
-21,890
-22,463
-29,819
Total Expenses
11,385
30,744
22,564
35,860
36,625
Net Income from Continuing & Discontinued Operation
-16,105
-35,090
-31,398
-23,763
-31,831
Normalized Income
-15,986.5000
-35,336
-25,952
-24,583
-32,751.1600
Interest Expense
6,178
5,711
3,805
2,463
1,556
Net Interest Income
-6,577
-6,148
-4,309
-2,950
-1,665
EBIT
-9,925
-29,377
-27,591
-21,297
-30,238
EBITDA
-9,547
-12,173
-27,036
-20,741
-29,687
Reconciled Cost of Revenue
2,171
1,980
672
59
--
Reconciled Depreciation
378
17,204
555
556
551
Net Income from Continuing Operation Net Minority Interest
-16,105
-35,090
-31,398
-23,763
-31,831
Total Unusual Items Excluding Goodwill
-158
246
-5,446
820
1,278
Total Unusual Items
-158
246
-5,446
820
1,278
Normalized EBITDA
-9,389
-12,419
-21,590
-21,561
-30,965
Tax Rate for Calcs
0.0003
--
--
--
0.0003
Tax Effect of Unusual Items
-39.5000
--
--
--
357.8400
12/31/2020 - 2/12/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

HQ1.MU Oruka Therapeutics Inc. R
7.05
+6.02%
 
ARDX.MX Ardelyx, Inc.
105.50
0.00%
 
RPD.MU Royalty Pharma plc
28.20
0.00%
 
B9A.F BioArctic AB (publ)
16.79
+12.46%
 
BT3.BE Lineage Cell Therapeutics Inc
0.3800
-5.47%
 
2HA.F Spero Therapeutics, Inc.
0.6170
+16.64%
 
05Y.MU Vivoryon Therapeutics NV
1.7440
-4.49%
 
ICY.HA Incyte Corp
52.14
+1.76%
 
P0F.F Egetis Therapeutics AB (publ)
0.2955
-4.68%
 
PROT Proteonomix, Inc.
0.0000
0.00%